Tinnitus 2026: What the New Evidence Actually Shows

/// AUDIO TRANSMISSION · EN

Listen to this transmission · 2-host podcast version

0:00 / 16:07

/// AUDIO TRANSMISSION · ES

Listen to this transmission · 2-host podcast version

0:00 / 16:35

The 2023 FDA De Novo Class II authorization of Lenire — a bimodal sound-and-tongue stimulation device — was the first regulatory approval of any device for tinnitus. Internet-delivered CBT proved non-inferior to in-person CBT in a randomized head-to-head trial. No over-the-counter supplement has comparable evidence. The ringing, in most cases, does not stop. What the best available interventions can change is how much that ringing controls your life.

TL;DR — Tinnitus 2026: what's real

• Lenire (bimodal sound + tongue stimulation) got FDA De Novo Class II authorization in March 2023 — the first device of its kind. THI reductions of 18–28 points across 3 trials. Effect is durable at 12-month follow-up.
• Internet-delivered CBT is non-inferior to in-person CBT (Beukes 2018, JAMA Otolaryngology). Game-changing for the 90% of sufferers without specialist access.
• CBT reduces tinnitus distress (Hedges' g = 0.70), not loudness. This distinction is everything — and routinely conflated in marketing.
• No OTC supplement has RCT evidence for tinnitus. Lipo-Flavonoid: one trial, no significant effect. Ginkgo, Tinnitus 911, herbal complexes: zero qualifying RCTs.
• 740 million adults worldwide affected (JAMA Neurology 2022). $26 billion US economic cost annually.

---

In 1995, tinnitus researchers had roughly the same toolkit they had in 1975. Sound masking. Tricyclic antidepressants used off-label. A new protocol called Tinnitus Retraining Therapy that combined counseling with low-level noise generators. The field moved slowly, the treatments were modest, and the supplement industry moved in to fill the vacuum — selling bioflavonoid pills and "herbal complexes" to 25 million Americans who reported persistent ringing with nowhere scientifically credible to go.

For the next 25 years, the story stayed largely the same. Protocols promised relief. Most delivered nothing beyond placebo. The Tinnitus Handicap Inventory (THI) — the field's 100-point distress scale — barely moved in underpowered trials. The patient forums filled with despair.

Then 2023 happened. And 2024.

In March 2023, the U.S. Food and Drug Administration granted De Novo Class II authorization to a device called Lenire — the first bimodal neuromodulation system ever to receive FDA clearance for tinnitus. That same period saw a wave of internet-delivered CBT trials report results that matched or exceeded in-person therapy, at a fraction of the access cost. The evidence frontier moved more in 18 months than in the prior decade combined.

This is a map of where that frontier now stands: what holds up under scrutiny, what never held up but is still being sold, and what's promising but not yet ready to recommend.

How many people have tinnitus, and how is it underserved?

Start with the scale. A 2022 systematic review and meta-analysis published in JAMA Neurology — the most comprehensive global estimate to date — found that tinnitus affects 14.4% of the adult population worldwide, or approximately 740 million adults.

"The pooled prevalence of any tinnitus among adults was 14.4%, while the pooled prevalence of severe tinnitus was 2.3%."

In the United States, the Hearing Health Foundation estimates 25 million Americans report tinnitus lasting five or more consecutive minutes in the past year. The American Tinnitus Association puts direct economic costs at an estimated $26 billion annually in lost worker productivity. These numbers sit behind approximately one million Google searches per month — a query volume driven largely by people in distress, not by casual curiosity.

Tinnitus is not a disease. That distinction is important and frequently skipped by product marketers. Tinnitus is a symptom — the auditory system's output of a phantom signal. Its causes are heterogeneous: noise-induced cochlear damage, age-related hearing loss, ototoxic medications, middle ear pathology, vascular anomalies, and in some cases no identifiable cause at all. This heterogeneity is why "a tinnitus cure" has remained elusive. You cannot treat a symptom with a single intervention when the underlying mechanisms differ across patients. Treatment that reorganizes auditory cortex may help noise-induced cases and do nothing for vascular-origin tinnitus.

That structural reality is the first thing most tinnitus product marketing fails to disclose.

Does Lenire actually work for tinnitus?

Lenire is a bimodal neuromodulation device developed by Neuromod Devices in Dublin, Ireland. It works by delivering synchronized sound to the ears and mild electrical stimulation to the tongue via a mouthpiece — simultaneously. The hypothesis: pairing auditory and somatosensory input triggers neuroplasticity in the auditory cortex, gradually reducing the brain's representation of the tinnitus signal.

The evidence trail runs through three controlled trials.

TENT-A1 (2020) — Brian Conlon at Beaumont Hospital Dublin and colleagues enrolled 326 participants in a randomized trial published in Science Translational Medicine. After 12 weeks of treatment, 86.2% of treatment-compliant participants showed improvement in THI score, and 80.1% maintained that improvement at 12-month follow-up. The trial did not use a sham control arm — a methodological limitation the authors acknowledged.

"86.2% of treatment-compliant participants had improvements in THI score at end of treatment."

TENT-A2 (2022) — A larger randomized trial in Scientific Reports (n = 298) compared different bimodal stimulation parameter settings. At 12 weeks, the average THI reduction across both arms was 18.5 points. At 12-month follow-up without further treatment, the average long-term THI reduction was 20.2 points — suggesting durable effect. The field considers a 6–7 point THI reduction the minimal clinically important difference; an 18–20 point reduction is substantial.

"There was an average reduction across both arms of 18.5 points for THI... improvements were sustained for 12 months after treatment was withdrawn."

TENT-A3 (2024) + FDA submission — The pivotal trial that preceded FDA authorization enrolled 112 participants across three independent sites, comparing 6 weeks of bimodal stimulation against 6 weeks of sound therapy alone. This time with an active control. The bimodal arm outperformed. Over the full trial, 79.4% of patients experienced a clinically significant improvement. Real-world evidence from 204 additional patients in post-authorization use showed a mean THI improvement of 27.8 points, with no device-related serious adverse events.

"Lenire is intended to provide bimodal (sound and transmucosal electrical tongue) stimulation to temporarily relieve the symptoms of tinnitus in patients 18 years of age and older suffering from at least moderate tinnitus."

"79.4% of patients experienced a clinically significant improvement across the full TENT-A3 trial population."

One caveat the FDA authorization itself makes clear: Lenire provides temporary relief of tinnitus symptoms, not a cure. The mechanism appears to require the treatment course to maintain effect — which is an important commercial reality the device's marketing sometimes understates.

The De Novo pathway also deserves explanation. De Novo is not the same as a full FDA approval for established device classes. It establishes a new Class II device category for novel technologies without a direct predicate, subject to general controls and special controls. It means FDA reviewed the evidence and found it sufficient for clearance — but it is not the gold standard of a Phase III pharmaceutical approval. The evidence base for Lenire is real and relatively robust for the field; it should not be inflated into something the regulatory process did not claim.

Is internet-based CBT as effective for tinnitus as in-person?

The most consequential shift in tinnitus care may not be the device. It may be access.

Eldré Beukes at Anglia Ruskin University has run the largest systematic program of internet-delivered cognitive behavioral therapy (iCBT) for tinnitus in any English-language setting. The 2018 randomized clinical trial published in JAMA Otolaryngology–Head & Neck Surgery compared guided iCBT against face-to-face clinical care in 102 participants. The result: iCBT was non-inferior to in-person CBT on tinnitus distress reduction. Not worse. On insomnia outcomes, iCBT actually outperformed the in-person arm.

"Guided internet-based CBT was non-inferior to face-to-face clinical care for treatment of tinnitus; both produced comparable reductions in tinnitus distress."

Non-inferiority matters here for a specific reason: access to in-person audiologist-guided CBT for tinnitus is extraordinarily limited. Waiting lists in the UK average 18 months. In the United States, specialist audiologists trained in tinnitus CBT are concentrated in major metropolitan areas. If iCBT produces equivalent outcomes, it changes the equation for the 90% of tinnitus sufferers who have no realistic path to in-person specialist care.

The 2024 meta-analysis in PMC covering internet-based therapies for tinnitus (21 RCTs, 1,847 participants) confirmed Beukes' direction of effect. Internet-based CBT and mindfulness consistently outperformed waitlist controls on tinnitus distress, tinnitus-related cognitions, anxiety, depression, and insomnia.

"Internet-based CBT and mindfulness interventions for tinnitus consistently outperformed waitlist controls on measures of tinnitus distress and associated mental health outcomes."

Does CBT actually reduce tinnitus loudness?

CBT for tinnitus works. The Cochrane Collaboration has reviewed it. The evidence is consistent. But the mechanism matters, and it is frequently misrepresented.

Henrik Hesser at Linköping University, Sweden, published the most cited meta-analysis: 15 studies, 1,091 participants. For tinnitus distress specifically, CBT versus passive control yielded a Hedges's g of 0.70 — a medium-to-large effect size. Against active controls it was 0.44 — still clinically meaningful.

"CBT compared with passive control yielded a statistically significant mean effect size for tinnitus-specific measures (Hedges's g = 0.70)."

Read that carefully. The effect is on distress — the suffering, the emotional impact, the quality-of-life impairment. Not on tinnitus loudness. The meta-analytic literature is consistent on this point: CBT does not reduce how loud patients perceive their tinnitus. It reduces how much that perception controls their life.

This distinction is everything. Most sufferers come in wanting the ringing to stop. What CBT delivers is a different outcome: the ringing remains, but its grip on attention, sleep, and mood loosens. For people with severe tinnitus-related handicap, that functional improvement can be transformative. But it should be explained accurately, not sold as something it isn't.

The Cochrane review on CBT for tinnitus in adults (2020) reached a similar conclusion: low-to-moderate certainty evidence that CBT reduces the negative impact of tinnitus on quality of life at end of treatment, with no effect on loudness.

This is also the honest framing for Tinnitus Retraining Therapy. TRT combines directive counseling with sound enrichment (low-level broadband noise). The Cochrane TRT review found limited evidence of efficacy — a single included study showing benefit, but rated low quality. A 2021 meta-analysis of 13 RCTs found TRT improved outcomes when added to medical treatment, but the underlying evidence was rated low quality with high risk of bias. TRT may help. The evidence that it outperforms well-delivered CBT is not there.

Do tinnitus supplements like Lipo-Flavonoid work?

Here is what the supplement industry has established beyond dispute: there are no over-the-counter dietary supplements with RCT-level evidence for tinnitus.

Lipo-Flavonoid (bioflavonoids derived from lemon extract) has been marketed for tinnitus in the United States for more than 60 years. In that time, one adequately designed randomized controlled trial examined it — a placebo-controlled study of Manganese and Lipoflavonoid Plus published in Otolaryngology–Head and Neck Surgery. The result: no significant improvement in tinnitus symptoms in either active arm.

"We were unable to conclude that either manganese or Lipoflavonoid Plus is an effective treatment for tinnitus based on this randomized controlled trial."

The American Academy of Otolaryngology–Head and Neck Surgery does not recommend Lipo-Flavonoid for tinnitus. Neither does the American Tinnitus Association. The product continues to be sold in pharmacies throughout the United States.

"Tinnitus 911," "Ring Ease," "TruSound," and similar herbal complexes — primarily zinc, magnesium, ginkgo biloba, and vitamin blends — have no peer-reviewed RCT evidence of efficacy for tinnitus. A 2018 Otolaryngology literature review bluntly titled "Over-the-Counter Tinnitus 'Cures': Marketers' Promises Do Not Ring True" reviewed the evidence for these products and found a consistent pattern: advertising claims that outstrip what any controlled study has demonstrated.

"No studied over-the-counter tinnitus product has demonstrated replicable, long-term reduction of tinnitus impact in excess of placebo effects."

Ginkgo biloba has been tested in multiple trials. A 2022 Cochrane-adjacent systematic review found no clear benefit for tinnitus across adequately powered studies. The European Food Safety Authority has found insufficient evidence to support health claims for lemon bioflavonoids — banning such claims within the EU. The U.S. market faces no equivalent regulatory restriction, which is why the shelves are still stocked.

The structural driver is straightforward: supplements are regulated as food, not drugs. They require no proof of efficacy before sale. The tinnitus supplement market is not a conspiracy. It is a regulatory arbitrage.

What new tinnitus treatments are coming after Lenire?

Two neuromodulation approaches sit in pre-clinical or early-trial territory. Neither is ready for routine recommendation. Both are worth tracking.

Vagus nerve stimulation (VNS) paired with tones was pioneered by Michael Kilgard and Navzer Engineer at the University of Texas at Dallas. The theoretical basis: surgically implanted VNS paired with tone presentations drives targeted cortical reorganization, potentially reversing the maladaptive plasticity that generates tinnitus. Animal studies established proof of concept. The first human pilot — Tyler et al. (2017), Scientific Reports, n = 30 — found 50% of the paired-VNS group showed clinically meaningful improvement versus 28% in the sham-stimulation control at 6 weeks.

"50% of participants in the paired VNS group showed clinically meaningful improvements compared to 28% in controls."

The limitation: this approach requires surgical implantation of a vagus nerve stimulator. That is a significant procedural burden. Non-invasive transcutaneous auricular VNS is being studied as an alternative, with a 2024 Frontiers in Neuroscience narrative review concluding that early evidence is "encouraging but not yet definitive."

Repetitive transcranial magnetic stimulation (rTMS) for tinnitus has a longer history and, unfortunately, a more ambiguous one. A 2022 meta-analysis of RCTs in PMC covering 9 studies found rTMS produced modest improvement, but several well-controlled trials have found active rTMS no more effective than sham. A 2023 review in JAMA Otolaryngology concluded that numerous unresolved variables — coil placement, stimulus frequency, session count, patient selection — prevent any protocol from being recommended as standard care.

"Active rTMS was no more effective than sham rTMS as a tinnitus treatment method in several well-controlled trials; inconsistency across studies prevents recommendation."

Pharmacology deserves a single frank sentence: no drug has ever received FDA approval for primary tinnitus. Antidepressants and anxiolytics may reduce the associated psychological burden; they do not reduce tinnitus itself. Acamprosate showed a signal in one trial. That is the field's best pharmacological result. It has not been replicated at scale.

How do tinnitus treatments compare on cost and evidence?

Intervention	Evidence Tier	Avg THI Reduction	Effect on Loudness	Approx. Cost (USD)	Availability
CBT (in-person)	Strong (Cochrane, multiple RCTs)	Hesser g=0.70 vs control	None	$800–3,000+	Very limited specialist access
Internet CBT (iCBT)	Strong (RCT, non-inferior to in-person)	Comparable to in-person	None	$150–500	Growing (apps, audiologist-guided programs)
Lenire (bimodal)	Moderate-Strong (FDA De Novo, 3 trials)	18.5–27.8 pts	Partial/indirect	$3,000–5,000	100+ US audiology clinics
TRT	Weak (Cochrane: low quality evidence)	Variable	None documented	$1,500–4,000	Specialist only
Sound masking / hearing aids	Moderate for co-existing hearing loss	Modest	Masking only	$1,500–7,000	Audiology clinics
Notched music therapy	Weak-Inconclusive (replications inconsistent)	Inconsistent	Inconsistent	$0–$50 (apps)	Wide (apps)
rTMS	Inconclusive (no consensus protocol)	Mixed	Mixed	$3,000–8,000	Specialty clinics
VNS paired stimulation	Early (n=30 pilot)	Insufficient data	Insufficient data	Experimental	Clinical trials only
Lipo-Flavonoid / supplements	None (single failed RCT)	0	0	$20–60/month	Pharmacies nationwide

What we can say. What we can't.

We can say: Lenire is the first device to receive FDA De Novo Class II authorization for tinnitus, based on three controlled trials showing average THI reductions of 18–28 points — substantially above the 6–7 point minimal clinically important difference. The effect appears durable at 12-month follow-up without continued treatment. No device-related serious adverse events were reported across the pivotal trial populations.

We can say: internet-delivered CBT is non-inferior to in-person CBT for tinnitus distress reduction in the largest head-to-head randomized trial to date. For the 25 million Americans with limited access to specialist audiologists, this finding changes the practical options available.

We can say: CBT in all its delivery formats reduces tinnitus distress (Hedges's g = 0.70 vs passive control). It does not reduce tinnitus loudness. These are different outcomes. Both are real. Only one is consistently achievable.

We can say: there are no over-the-counter supplements with RCT-level evidence of efficacy for tinnitus. Not Lipo-Flavonoid. Not ginkgo biloba. Not any "Tinnitus 911" formulation. They are legal products. They are not supported by controlled evidence.

We can't say: that any current treatment cures tinnitus in the sense of eliminating the perception permanently in most patients.

We can't say: that Lenire works equally across all tinnitus subtypes — the pivotal trials enrolled patients with moderate-to-severe THI scores, primarily noise-induced or age-related tinnitus.

We can't say: that VNS-paired stimulation or any pre-clinical approach will translate to routine clinical use. Promising pilot results have a high failure rate in tinnitus research specifically.

We can't say: why 30 years of documented placebo-equivalent supplement products continue to dominate the consumer tinnitus market while evidence-based treatments remain behind specialist-access walls.

---

The honest clinical picture in 2026: tinnitus distress is treatable. Loudness reduction remains rare. The mechanisms are real, the tools are improving, and access to validated interventions is still limited by cost, geography, and the regulatory gap that keeps supplements on pharmacy shelves and Lenire out of reach for most sufferers.

The gap between what exists and who can get it isn't a research problem anymore.

What closes that gap — and who benefits from it staying open — is worth asking.

---

For related evidence maps, see anxiety natural remedies: what the trials show and insomnia: the evidence-based options.

FAQ

What is the best treatment for tinnitus in 2026?

No single treatment eliminates tinnitus. The strongest evidence points to two interventions: Lenire (bimodal sound + tongue stimulation, FDA De Novo authorized March 2023), which reduced THI distress scores by 18–28 points across three trials, and cognitive behavioral therapy, which reduces tinnitus-related distress by a Hedges' g of 0.70 — without reducing loudness. Internet-delivered CBT is non-inferior to in-person CBT.

How much does Lenire cost?

Lenire is available at 100+ US audiology clinics and costs approximately $3,000–$5,000 for the treatment course. It received FDA De Novo Class II authorization (DEN210033) in March 2023. It is not FDA-approved as a cure — it is authorized to temporarily relieve tinnitus symptoms in adults 18+ with at least moderate tinnitus.

Does CBT cure tinnitus?

No. CBT does not reduce tinnitus loudness. What the evidence consistently shows (Hesser et al. 2011, 15 studies, 1,091 participants; Cochrane 2020) is that CBT reduces tinnitus distress — the emotional impact, sleep disruption, and quality-of-life impairment that tinnitus causes. The ringing stays; its grip on daily life loosens. That distinction matters and is frequently elided in product marketing.

Do tinnitus supplements work?

No OTC tinnitus supplement has RCT-level evidence of efficacy. Lipo-Flavonoid — the category's longest-standing product — failed its one adequately designed placebo-controlled trial (Le et al. 2016). Ginkgo biloba, zinc, magnesium complexes, and branded formulations like "Tinnitus 911" have zero qualifying controlled trials. Neither the AAO-HNS nor the American Tinnitus Association recommends any OTC supplement for tinnitus.

What is the latest research on tinnitus treatment?

The 2023–2026 frontier includes: Lenire's FDA authorization (first-ever for a tinnitus device, March 2023); a 2024 PMC meta-analysis of 21 iCBT RCTs confirming internet-delivered CBT efficacy; early-phase VNS-paired-tone stimulation trials (Tyler et al. n=30, 50% responder rate); and inconclusive rTMS evidence pending consensus protocol. No drug has received FDA approval for primary tinnitus.

Sources

• Haider, H. F., et al. (2022). Global Prevalence and Incidence of Tinnitus: A Systematic Review and Meta-analysis. JAMA Neurology.
• Conlon, B., et al. (2020). Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study. Science Translational Medicine, abb2830.
• Conlon, B., et al. (2022). Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial. Scientific Reports.
• Conlon, B., et al. (2024). Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial. Nature Communications.
• FDA CDRH. (2023). De Novo Authorization DEN210033 — Lenire combined acoustic and electrical external stimulation device for the relief of tinnitus. U.S. Food and Drug Administration.
• Beukes, E. W., et al. (2018). Effectiveness of Guided Internet-Based Cognitive Behavioral Therapy vs Face-to-Face Clinical Care for Treatment of Tinnitus: A Randomized Clinical Trial. JAMA Otolaryngology–Head & Neck Surgery.
• Roos, I., et al. (2024). Efficacy of Internet-Based Therapies for Tinnitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMC / Systematic Review.
• Hesser, H., et al. (2011). A systematic review and meta-analysis of randomized controlled trials of cognitive-behavioral therapy for tinnitus distress. Clinical Psychology Review.
• Cochrane Collaboration. (2020). Cognitive behavioural therapy for adults with tinnitus. Cochrane Database of Systematic Reviews.
• Cochrane Collaboration. (2022). Tinnitus Retraining Therapy (TRT) for tinnitus. Cochrane Database of Systematic Reviews.
• Le, T. N., et al. (2016). Manganese and Lipoflavonoid Plus to Treat Tinnitus: A Randomized Controlled Trial. Otolaryngology–Head and Neck Surgery.
• Park, S., & Moon, I. S. (2018). Over-the-Counter Tinnitus "Cures": Marketers' Promises Do Not Ring True. Otolaryngology–Head and Neck Surgery (correspondence).
• Tyler, R. S., et al. (2017). Vagus Nerve Stimulation Paired with Tones for the Treatment of Tinnitus: A Prospective Randomized Double-blind Controlled Pilot Study in Humans. Scientific Reports.
• Tao, H., & Fang, S. (2022). A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effect of Transcranial Magnetic Stimulation on Tinnitus Management. PMC.
• Hearing Health Foundation. (2024). Hearing Loss & Tinnitus Statistics. hearinghealthfoundation.org.
• American Tinnitus Association. (2024). Medications — Therapy and Treatment Options. ata.org.